Authors: Philip Fodstad Sinan Dheyauldeen Marit Rinde Gregor BachmannHarildstad
Publish Date: 2010/09/08
Volume: 90, Issue: 5, Pages: 611-612
Abstract
For the treatment of epistaxis in patients with HHT several therapeutic drugs have been recommended Tranexamic acid has shown to have some effect lowdose estrogen–progesterone showed efficacy in an uncontrolled study and oral tamoxifen was shown to be effective in a randomized placebocontrolled study 4 5 From a case report bevacizumab had a profound effect on a patient with nonbleeding vascular AVMs 6Bevacizumab was effective in this patient with anemia due to severe HHT also when given in intervals of 3 weeks In cases with severe visceral AVMs and/or severe intractable and transfusiondependent epistaxis due to HHT we recommend a 45month treatment regime with 5 mg/kg of bevacizumab given in 3week intervalsThis article is published under an open access license Please check the Copyright Information section for details of this license and what reuse is permitted If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and reuse information please contact the Rights and Permissions team
Keywords: